Overall survival assessment in cancer drug trials : a luxury or a necessity?
Source
The lancet oncology - ISSN 1470-2045-26:11 (2025) p. 1402-1404
Success in oncology phase 3 trials : a small P value or patient value
Source
Journal of the National Cancer Institute - ISSN 0027-8874-117:9 (2025) p. 1761-1763
Assessing clinical value of new treatment strategies : ESMO-MCBS and ASCO-VF evaluation in phase III trials at ASCO Annual Meeting 2022
Source
JCO oncology practice - ISSN 2688-1527-21:9 (2025) p. 1-11
Targeting fear of cancer recurrence with Internet-Based Emotional Freedom Techniques (iEFT) and Mindfulness Meditation Intervention (iMMI) (BGOG-gyn1b/REMOTE)
Source
Brain Sciences - ISSN 2076-3425-15:9 (2025) p. 1-16
Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
Source
The Breast - ISSN 0960-9776-81 (2025) p. 1-2